Comparison of Single Time-Point [111-In] Pentetreotide SPECT/CT With Dual Time-Point Imaging of Neuroendocrine Tumors

被引:16
|
作者
Wong, Ka Kit [1 ,2 ]
Wynn, Elizabeth A. [1 ,2 ]
Myles, Jamie [1 ,2 ]
Ackermann, Robert J. [1 ,2 ]
Frey, Kirk A. [1 ,2 ]
Avram, Anca M. [1 ,2 ]
机构
[1] Univ Michigan, Dept Nucl Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA
关键词
somatostatin receptor scintigraphy; neuroendocrine tumor; SPECT/CT; FUSION; CT; LOCALIZATION; SCINTIGRAPHY; TOMOGRAPHY; NEOPLASMS; IMPACT;
D O I
10.1097/RLU.0b013e3181feedc0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine whether single time-point single-photon emission computed tomography-computed tomography (SPECT/CT) somatostatin receptor imaging can replace traditional dual time-point planar and SPECT somatostatin receptor scintigraphy for evaluation of neuroendocrine tumors. Materials and Methods: Twenty-four patients (9 males, 15 females; mean age: 56 years; range: 14-82 years) underwent [111-In] pentetreotide scintigraphy, with planar whole-body images acquired at 24 and 48 hours after injection and abdominal SPECT/CT at 24 hours postinjection. Two blinded readers independently interpreted each study, using single time-point (24 hours planar and SPECT/CT) and separately using dual time-point (24-and 48-hours planar, and 24-hour SPECT without CT) image information. Consensus interpretations were compared with surgical pathology, or clinical and radiologic follow-up for at least 12 months. Results: Interobserver agreement was excellent (kappa = 0.86) for single time-point imaging, and good (kappa = 0.56) with dual time-point imaging. After consensus review, single time-point imaging identified pathologic lesions in 11 of 12 subjects with diagnosis of NET at follow-up, and in 0 of 12 subjects without NET (sensitivity 92%; specificity 100%). Dual time-point imaging performed similarly, but missed an additional NET case (sensitivity 83%; specificity 100%). After review of SPECT/CT, the readers considered that additional 48 hours imaging was not necessary in the majority of cases, indicating high degree of confidence with the single time-point imaging. Conclusion: [111-In] pentetreotide SPECT/CT imaging at 24 hours identifies pathologic disease sites and distinguishes physiologic activity equally well compared to traditional strategies using 2 imaging days. Routine use of SPECT/CT will allow single time-point imaging without loss of diagnostic accuracy, enhancing patient convenience, and clinical throughput.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 50 条
  • [1] Incremental Value of 111-In Pentetreotide SPECT/CT Fusion Imaging of Neuroendocrine Tumors
    Wong, Ka Kit
    Cahill, John M.
    Frey, Kirk A.
    Avram, Anca M.
    [J]. ACADEMIC RADIOLOGY, 2010, 17 (03) : 291 - 297
  • [2] When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
    Gang Cheng
    Drew A. Torigian
    Hongming Zhuang
    Abass Alavi
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 779 - 787
  • [3] When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
    Cheng, Gang
    Torigian, Drew A.
    Zhuang, Hongming
    Alavi, Abass
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (05) : 779 - 787
  • [4] Dual time-point quantitative SPECT-CT parathyroid imaging using a single computed tomography: feasibility and operator variability
    Razavi, Simin
    Ziebarth, Blair
    Klein, Ran
    Zeng, Wanzhen
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (01) : 3 - 9
  • [5] TIME-POINT SETS AND METER
    JOHNSON, WM
    [J]. PERSPECTIVES OF NEW MUSIC, 1984, 23 (01) : 278 - 293
  • [6] Choline PET/CT for the diagnosis of parathyroid adenoma: is there any role for a dual time-point imaging?
    Bastidas, J.
    Belaustegui, L. Garcia
    Bronte, A.
    Betech, V.
    De Andres, H. Casal
    Rosales, J. J.
    Minguez, F.
    Garcia Goni, M.
    Salvador, P.
    Arbizu, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S135 - S135
  • [7] Dual time-point imaging of lymphoma adenopathy using total-body FDG PET/CT
    Shrestha, Bimash
    Singh, Shashi
    Motamedi, Niloofaralsadat
    Werner, Thomas
    Nardo, Lorenzo
    Abdelhafez, Yasser
    Alavi, Abass
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [8] Evaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer
    Tasdemir, Bekir
    Guzel, Yunus
    Komek, Halil
    Can, Canan
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (12) : 1322 - 1327
  • [9] Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience
    Vento, A.
    Laudicella, R.
    Minutoli, F.
    Romeo, D.
    Russo, S.
    Cardile, D.
    Filice, R.
    Comis, A. D.
    Mirabile, A.
    Pagano, B.
    Bisdas, S.
    Baldari, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S442 - S442
  • [10] Dual time-point 18F-Choline PET/CT imaging for improved diagnostic image quality
    de Bloeme, M.
    Trinckauf, J.
    Hany, T. F.
    Berthold, T.
    Knoefel, S.
    Beutel, D.
    Epp, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S486 - S486